Scotland Leads UK with Newborn Screening for Spinal Muscular Atrophy

Scotland has taken a significant step in the early detection and treatment of spinal muscular atrophy (SMA), a rare genetic condition that causes progressive muscle wastage, by becoming the first part of the UK to screen newborn babies for the condition.

The screening, which is part of the existing heel prick test offered to all parents in Scotland about four days after birth, is funded by the Scottish government and pharmaceutical company Novartis. The goal is to assess how well screening can detect SMA earlier, allowing babies to receive treatment as soon as possible.

SMA affects an estimated 1 in 14,000 births worldwide and impacts movement, breathing, and swallowing. Without treatment, it can limit life expectancy to two years. The condition was brought to wider attention after former Little Mix singer Jesy Nelson revealed in January that her twin daughters had been diagnosed with SMA.

Campaigners, who have long advocated for newborn testing, hope the Scottish pilot will result in approval for the heel prick test across the UK. Giles Lomax, chief executive of SMA UK, said the screening pilot in Scotland would be “a huge impetus for other parts of the UK to speed up their own testing plans”. He hopes the Scotland trial will provide data that would convince the UK National Screening Committee to approve UK-wide testing.

There is no cure for SMA, but there are now three NHS-funded drug treatments available. Lomax emphasized that with these treatments and newborn screening, “the future for anyone diagnosed with SMA is very different compared to their peers who were diagnosed symptomatically. It basically gives children the life they deserve.”